Depression Treatment – Page 2

Biological markers of treatment response to serotonergic psychedelic therapies: a systematic review

mycolabadmin

This review examines how scientists can predict which patients will benefit most from psychedelic-assisted therapy for depression by measuring biological markers in the brain and blood. Researchers found that certain brain changes and protein levels—particularly involving the amygdala, specific brain regions, and inflammation markers—appear linked to treatment success. While the current studies are small, they suggest that measuring these biological markers could eventually help doctors personalize psychedelic treatments for depression.

Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication

mycolabadmin

Researchers tested whether people with severe depression could take psilocybin (a compound from certain mushrooms) while staying on their antidepressant medications. In this study of 19 people, those who received psilocybin with psychological support while continuing their SSRI showed significant improvement in depression symptoms over three weeks, with response rates of 42%. Side effects were mostly mild and temporary, suggesting this approach may be safe and effective without requiring patients to stop their current antidepressants.

Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis

mycolabadmin

This comprehensive analysis of clinical trials found that psilocybin, a compound found in certain mushrooms, shows promise as a treatment for depression compared to placebo. The treatment was particularly effective for patients with depression related to serious illness, those using self-reported symptom assessments, older adults, and those with prior experience with psychedelics. While side effects were minimal and temporary, researchers emphasize that more research is needed to fully understand how expectancy and individual factors influence treatment outcomes.

Effects and safety of Psilocybe cubensis and Panaeolus cyanescens magic mushroom extracts on endothelin-1-induced hypertrophy and cell injury in cardiomyocytes

mycolabadmin

Researchers tested whether magic mushrooms containing psilocybin could be safely used by people with heart failure, especially those dealing with depression. Using laboratory rat heart cells, they found that extracts from Psilocybe cubensis and Panaeolus cyanescens mushrooms actually protected heart cells from damage and reduced harmful inflammation. The mushroom extracts worked similarly to standard heart medications at the tested concentrations, suggesting they may be safe for use under controlled medical supervision.

Hype or hope? Ketamine for the treatment of depression: results from the application of deep learning to Twitter posts from 2010 to 2023

mycolabadmin

Researchers analyzed over 18,000 Twitter posts from 2010 to 2023 to understand what the public thinks about using ketamine to treat depression. They found that public opinion became much more positive after the FDA approved ketamine as a depression treatment in 2019. Most discussions consisted of personal stories from people who found ketamine helpful, especially those whose depression didn’t respond to other medications. While some people expressed caution and concerns, overall the public seems hopeful about ketamine’s potential.

Interactions between classic psychedelics and serotonergic antidepressants: Effects on the acute psychedelic subjective experience, well-being and depressive symptoms from a prospective survey study

mycolabadmin

This study examines how antidepressant medications (like SSRIs) affect the experience of classic psychedelics such as psilocybin and LSD. Researchers found that people taking these antidepressants experienced less intense emotional and mystical effects from psychedelics, but surprisingly, both groups showed similar improvements in mood and well-being several weeks later. This raises important questions about whether patients need to stop their antidepressants before using psychedelics therapeutically.

The effect of psilocybin on empathy and prosocial behavior: a proposed mechanism for enduring antidepressant effects

mycolabadmin

This review examines how psilocybin may help treat depression by increasing empathy and prosocial behavior. While psilocybin leaves the body within hours, its antidepressant effects can last months, and researchers believe empathy and helping others may explain this lasting benefit. The authors suggest psilocybin starts a positive cycle where increased empathy leads to helping others, which boosts mood and well-being, which further reinforces empathetic behavior.

Psychedelic-assisted therapy – supposedly paradigm-shifting research with poor attempts at hypotheses falsifying and questionable ethics

mycolabadmin

This paper critically examines recent clinical trials testing MDMA and psilocybin for treating PTSD and depression. While these trials reported promising results, the author identifies serious scientific and ethical problems: participants could tell whether they received the drug or placebo due to its strong effects, researchers and therapists who strongly believed in the treatment may have unconsciously influenced patient responses, and negative side effects may have been downplayed. The author argues that without fixing these problems, the entire field of psychedelic therapy research could lose credibility.

CORRECTION: Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis

mycolabadmin

A major research study examining psilocybin’s effectiveness for treating depression has been corrected due to mathematical and data handling errors. The researchers fixed these issues by recalculating statistics and removing duplicate data from their analysis. While the main conclusions remained similar after correction, the authors emphasize this research is still preliminary and should lead to further study before clinical use.

Therapeutic and legal aspects of psilocybin in cancer-related depression

mycolabadmin

This paper examines how psilocybin, a naturally occurring psychoactive compound from mushrooms, could help cancer patients—especially those with head and neck cancer—who develop severe depression after surgery. Unlike traditional antidepressants that take weeks to work, psilocybin acts within hours, making it potentially ideal for patients needing rapid mental health support following disfiguring surgical procedures. However, while psilocybin is legal for medical or research use in several countries like Australia and Portugal, it remains restricted in Poland and many other places, creating legal barriers to its clinical implementation.

Research Topic: Depression Treatment